{"protocolSection":{"identificationModule":{"nctId":"NCT06211712","orgStudyIdInfo":{"id":"KY2023-707"},"organization":{"fullName":"Huashan Hospital","class":"OTHER"},"briefTitle":"Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion","officialTitle":"Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study","acronym":"HEAL"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-12-28","studyFirstSubmitQcDate":"2024-01-09","studyFirstPostDateStruct":{"date":"2024-01-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-09","lastUpdatePostDateStruct":{"date":"2024-01-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Qiang Dong","investigatorTitle":"Chief physician","investigatorAffiliation":"Huashan Hospital"},"leadSponsor":{"name":"Huashan Hospital","class":"OTHER"},"collaborators":[{"name":"Shanghai Stroke Association","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficacy of Human Urinary Kallidinogenase combined with endovascular therapy in acute ischemic stroke (AIS) patients with large vessel occlusion.","detailedDescription":"A prospective, randomized, double-blind, placebo-controlled, multi-center study of Human Urinary Kallidinogenase or Placebo, combined with endovascular therapy for AIS patients with large vessel occlusion.\n\nApproximately 120 eligible subjects will be randomized (1:1) to receive one of the following treatments for 10 days:\n\n* Human Urinary Kallidinogenase combined with endovascular therapy (non-bridged)\n* Placebo combined with endovascular therapy (non-bridged) Primary efficacy of Human Urinary Kallidinogenase will be evaluated at 90 days. The safety of Human Urinary Kallidinogenase will be evaluated through 90 days. End of study evaluation will occur at day 90 or premature discontinuation."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"A randomized, double-blind, placebo-controlled study","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":120,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Human Urinary Kallidinogenase","type":"EXPERIMENTAL","interventionNames":["Drug: Experimental: Human Urinary Kallidinogenase"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Comparator: Placebo"]}],"interventions":[{"type":"DRUG","name":"Experimental: Human Urinary Kallidinogenase","description":"Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.","armGroupLabels":["Human Urinary Kallidinogenase"]},{"type":"DRUG","name":"Placebo Comparator: Placebo","description":"Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"ASPECT score evaluated using routine CT","timeFrame":"day 7"},{"measure":"Modified Rankin Scale (mRS) score","timeFrame":"day 90"}],"secondaryOutcomes":[{"measure":"Barthel index","timeFrame":"on day of discharged from hospital and day 90"},{"measure":"Percentage of TIC ≥ 2b and mRS ≥ 3","timeFrame":"on day 90"},{"measure":"Changes of NIHSS score from baseline","timeFrame":"on day 1, 4, 7 and 11"},{"measure":"Changes of vital signs from baseline","timeFrame":"on day 1, 4, 7 and 11"},{"measure":"Changes of blood inflammatory index and vascular endothelial cell growth index","timeFrame":"from day 1 on day 7"},{"measure":"MRI and / or DWI examined","timeFrame":"within 11 days to determine the infarct volume"},{"measure":"Recurrence rate of ischemic stroke","timeFrame":"within 90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participant with acute anterior circulation ischemic stroke receiving endovascular treatment within 24 hours (non-bridged).\n2. Age ≥18 years old and ≤80 years old.\n3. The mRS score was 0-1 before onset.\n4. ASPECT score of infarction on emergency CT ≥7.\n5. Emergency CTA indicating AIS with large vessel occlusion (internal carotid artery, M1 or M2 segment of middle cerebral artery).\n6. Emergency CTP or DWI suggesting infarct core body ≥10 mL and \\<100 mL, and low perfusion brain tissue volume/ infarct core volume\\> 1.2.\n7. Participant is willing and able to comply with the study protocol, and sign the informed consent form (patient or surrogate).\n\nExclusion Criteria:\n\n1. Participant with severe heart, liver and kidney dysfunction, coagulation dysfunction, intolerance to surgery, Human Urinary Kallidinogenase allergy, contrast agent allergy or other angiographic contraindications.\n2. CT or MRI showed intracranial hemorrhagic diseases (such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.).\n3. Participant with previous cerebral hemorrhage, brain tumor, brain trauma or other brain diseases.\n4. Taking ACEI antihypertensive drugs regularly and could not stop.\n5. Participant with major surgery or severe trauma in the past 2 weeks.\n6. Poor compliance and cannot fully follow the study protocol.\n7. Pregnancy or lactation.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Qiang Dong, doctor","role":"CONTACT","phone":"13701747065","email":"13701747065@163.com"},{"name":"Wenjie Cao, doctor","role":"CONTACT","phone":"13918206324","email":"wenjiecao@fudan.edu.cn"}],"overallOfficials":[{"name":"Qiang Dong, doctor","affiliation":"Huashan Hospital","role":"PRINCIPAL_INVESTIGATOR"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000007610","term":"Kallikreins"}],"ancestors":[{"id":"D000003029","term":"Coagulants"},{"id":"D000005303","term":"Fertility Agents, Male"},{"id":"D000005299","term":"Fertility Agents"},{"id":"D000012102","term":"Reproductive Control Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M10328","name":"Kallikreins","asFound":"eNOS","relevance":"HIGH"},{"id":"M5949","name":"Coagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}